FDA weighs easing restrictions on unproven peptide drugs
The FDA is considering an “Interim Access Policy” that could let it use enforcement discretion for some unproven peptide drugs, easing access through compounding pharmacies. The move comes as the agency reviews the drugs despite its scientists’ conclusions that they have not been adequately studied for safety or effectiveness and may cause harm.
In 2023, a dozen peptides were removed from the list of drugs compounding pharmacies can make; the FDA began reconsidering them in April. A newly appointed advisory panel later recommended restoring six of the first seven it considered, though several members had ties to peptide businesses or clinics. The FDA has not said whether it will adopt the recommendations, and formal rulemaking could take years; a consumer advocacy group has urged the agency to reject the panel’s advice.
- FDA proposal could ease access to unproven peptide drugs.
- FDA scientists say safety and effectiveness remain unestablished.
- Advisory panel recommended restoring six of seven peptides considered.
Both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
An interim access policy could give patients and clinicians more options while the FDA’s review and formal rulemaking continue, particularly for people who believe existing treatments do not meet their needs. Supporters may argue that carefully bounded access through compounding pharmacies, alongside clinical oversight, respects patient choice and avoids leaving decisions solely to a slow regulatory process.
The case against
The FDA’s scientists say these peptides have not been adequately studied for safety or effectiveness and may cause harm, so easing access could expose patients to poorly understood risks. Critics may argue that compounding and an interim policy cannot substitute for reliable evidence, and that the advisory panel’s recommendations warrant caution given some members’ ties to peptide businesses or clinics.
Health Medicine Research Science
Read the full article at the source →
Originally published by Ars Technica as “RFK Jr. proposes FDA look the other way on unproven peptides, report says”.